Noah Feder

Mr. Noah Feder

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2026 in The American Journal of Sports Medicine
Verified
Journal Article
Open access
RLRyan T Lin
Ryan T Lin
RGRyan Gilbert
Ryan Gilbert
SDSahil Dadoo
Sahil Dadoo
AKAmin Karimi
Amin Karimi
NFNoah Feder
Noah Feder
ALAlbert Lin
Albert Lin
Background: Previous literature has demonstrated that an increased number of preoperative anterior shoulder instability episodes is associated with recurrent anterior shoulder instability after arthroscopic Bankart repair (ABR). However, a threshold for the number of preoperative instability episodes that increases the risk of recurrent anterior shoulder instability is not well established. Purpose: To establish a threshold value for the number of preoperative instability episodes that predicts recurrent anterior shoulder instability after ABR and to compare glenoid bone loss, the Hill-Sachs interval, and the distance to dislocation between patients who have surpassed the threshold and those who have not. Study Design: Retrospective cohort study; Level of evidence, 3. Methods: This retrospective review included consecutive patients with “on-track” Hill-Sachs lesions who underwent primary ABR for anterior shoulder instability at a single institution between 2007 and 2019. Patients with an unknown number of preoperative instability episodes, >20% glenoid bone loss, 40 or <14 years were excluded. Logistic regression assessed associations between preoperative anterior shoulder instability episodes and recurrent anterior shoulder instability after ABR, defined as a recurrent subluxation or dislocation. Receiver operating characteristic analysis determined the optimal threshold of preoperative anterior shoulder instability episodes to predict recurrent anterior shoulder instability. Significance was set as P < .050. Results: A total of 151 patients (mean age, 20 ± 5 years; mean follow-up, 6.0 ± 3.1 years) were included, of whom 28 (19%) experienced recurrent anterior shoulder instability. Multiple thresholds showed increased odds of recurrent anterior shoulder instability: ≥2 preoperative anterior shoulder instability events (odds ratio [OR], 9.70 [95% CI, 2.63-35.70]; P = .001), ≥3 events (OR, 3.47 [95% CI, 1.37-8.80]; P = .009), and ≥4 events (OR, 3.08 [95% CI, 1.17-8.08]; P = .023). Receiver operating characteristic analysis revealed that ≥2 preoperative anterior shoulder instability events was the strongest predictor of recurrent anterior shoulder instability (area under the curve = 0.72). Conclusion: A threshold of ≥2 preoperative anterior shoulder instability episodes best predicted recurrent anterior shoulder instability after ABR. Stratification beyond 1 versus ≥2 preoperative anterior shoulder instability episodes did not increase predictive ability. This finding may help surgeons to counsel patients and consider earlier surgical stabilization in those who have sustained anterior shoulder instability episodes.

10 November 2025 in Genes
Verified
Journal Article
Open access
PDF file
JLJake Littman
Jake Littman
WYWentian Yang
Wentian Yang
NFNoah Feder
Noah Feder
AKAmr Kaadan
Amr Kaadan
AAAli Amin
Ali Amin
RARoy Aaron
Roy Aaron
McCune–Albright Syndrome (MAS) is a rare mosaic disorder caused by somatic activating mutations of the GNAS gene, resulting in constitutive Gsα signaling and a broad spectrum of clinical phenotypes. The syndrome typically presents with fibrous dysplasia (FD) of bone, café-au-lait macules, and endocrinopathies such as gonadotropin-independent precocious puberty, hyperthyroidism, and/or growth hormone excess. FD, which characterizes the skeletal phenotype, results in the replacement of normal bone with disorganized fibro-osseous tissue, often leading to pain, deformities, and increased risk of fractures. This review discusses the following: 1. The molecular biology of the GNAS locus and its relation to the pathophysiology of FD/MAS; 2. The skeletal manifestations of FD/MAS; 3. Bone biomechanics and organizational skeletal aberrations observed in FD/MAS; and 4. Current and future therapeutic strategies for patients with FD/MAS. While there is much current literature available regarding FD/MAS, this review specifically aims to outline core understandings and summarize some of the latest investigations into the genotypic and phenotypic foundations of the disorders, while shedding new light on the biomechanical aberrations observed in skeletal structure within them and comparing them to those observed in related disease processes such as osteoporosis and Paget’s disease.

1 April 2026 in Neurology Clinical Practice
Verified
Journal Article
Closed access
DHDaniel M. Hartung
Daniel M. Hartung
NGNico Gabriel
Nico Gabriel
WGWalid F. Gellad
Walid F. Gellad
TCTeresa Cameron
Teresa Cameron
NFNoah Feder
Noah Feder
IHInmaculada Hernandez
Inmaculada Hernandez
The objective of this study was to evaluate changes in net and list prices of branded multiple sclerosis (MS) disease-modifying therapies (DMTs) between 2013 and 2021. Using several pharmaceutical pricing and utilization data sources, we estimated list and net (after rebates and discounts) prices for branded monoclonal antibody (MAb) and oral DMTs. We calculated the inflation-adjusted list and net prices for each DMT, the manufacturer discount as a percentage of list price, the average annual change (AAC) in prices, and the cumulative change in list price offset by discounts. From 2013 to 2021, oral DMT list prices increased from $73,924 to $104,372 (5.3% AAC) while net prices rose from $69,187 to $82,181 (1.5% AAC) because of increasing manufacturer discounts (6.4%-21.2%). From 2014 to 2021, MAb DMT list prices increased from $70,320 to $92,109 (4.1% AAC), with net prices rising from $55,109 to $79,396 (3.0% AAC). Discounts offset 51%-86% of cumulative list price increases for oral DMTs (fingolimod, teriflunomide) vs 0%-35% for MAb DMTs. The divergent net pricing trends between oral and MAb DMTs may reflect increasing brand and generic competition among oral DMTs and a lack of biosimilar options among MAb DMTs.

27 July 2026 in JSES International
Verified
Journal Article
Open access
NANicholas F. Aloi
Nicholas F. Aloi
JWJacob N. Weinberg
Jacob N. Weinberg
NFNoah Feder
Noah Feder
HTHannah L. Tetreault
Hannah L. Tetreault
KNKrishna P. Nayak
Krishna P. Nayak
JFJohn R. Fowler
John R. Fowler

17 January 2026 in Cancer Letters
Verified
Journal Article
Open access
KCKasey R. Cargill
Kasey R. Cargill
NFNoah Feder
Noah Feder
TWTyler Wilhite
Tyler Wilhite
WGWalid F. Gellad
Walid F. Gellad
HSHeath D. Skinner
Heath D. Skinner
CWChristopher T. Wilke
Christopher T. Wilke